Investing.com - Cantor Fitzgerald reiterated its Overweight rating on Summit Therapeutics plc (NASDAQ:SMMT) following the FDA’s approval of a competing lung cancer treatment. The FDA on Monday ...

In trading on Tuesday, shares of Summit Therapeutics Inc (Symbol: SMMT) crossed above their 200 day moving average of $20.88, changing hands as high as $21.82 per share.

Nektar Therapeutics shares doubled in early trading Tuesday after the U.S. biotech firm said it reached its targets in a midstage study of its eczema treatment.

AstraZeneca and its partner Daiichi Sankyo have won approval from U.S. regulators for their precision drug Datroway to treat a type of lung cancer, marking the first approval of the therapy in ...

AstraZeneca and its partner Daiichi Sankyo have won approval from US regulators for their precision drug Datroway to treat a type of lung cancer, marking the first approval of the therapy in this ...

Investing.com - Cantor Fitzgerald reiterated its Overweight rating on Summit Therapeutics plc (NASDAQ: SMMT) following the FDA’s approval of a competing lung cancer treatment.

Sonoma, CA - Salesforce SVP Sunya Norman meets with Newsweek senior reporter Katherine Fung during Nexus Connect Meetings at the AI Impact Summit on Monday, June 23, 2025. NICK OTTO "It's helpful ...

On this news, Summit’s stock price fell $7.99 per share, or 30.5%, to close at $18.22 per share on May 30, 2025.

At AstraZeneca, we have a bold ambition to deliver 20 new medicines by 2030 – nine of which we’ve already delivered. While a new generation of therapies promises to redefine what is possible ...